Literature DB >> 21337095

Production of monoclonal antibodies.

J Freysd'ottir1.   

Abstract

The discovery of monoclonal antibodies (mAbs) produced by "hybridoma technology" by George Köhler and Cesar Milstein in 1975 has had a great impact both on basic biological research and on clinical medicine. However, this impact was not immediately recognized. It took around 10 years to appreciate the importance of using these mAbs in various fields of science other than immunology, such as cell biology, biochemistry, microbiology, virology, para-sitology, physiology, genetics, and molecular biology; and also in areas of clinical medicine, such as pathology, hematology, oncology, and infectious disease. The contribution of mAbs to science and clinical medicine was recognized in 1984 by the award of the Nobel Prize for Medicine to Köhler and Milstein.

Entities:  

Year:  2000        PMID: 21337095     DOI: 10.1385/1-59259-076-4:267

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  5 in total

Review 1.  Immunotherapy: an alternative promising therapeutic approach against cancers.

Authors:  Sneh Lata Gupta; Srijani Basu; Vijay Soni; Rishi K Jaiswal
Journal:  Mol Biol Rep       Date:  2022-06-27       Impact factor: 2.742

2.  Rituximab and biosimilars - equivalence and reciprocity.

Authors:  Zaina P Qureshi; Jametta S Magwood; Sarveshwari Singh; Charles L Bennett
Journal:  Biosimilars       Date:  2013-06-14

Review 3.  TSPAN8 as a Novel Emerging Therapeutic Target in Cancer for Monoclonal Antibody Therapy.

Authors:  Kyun Heo; Sukmook Lee
Journal:  Biomolecules       Date:  2020-03-03

Review 4.  Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.

Authors:  Eva Germovsek; Ming Cheng; Craig Giragossian
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

5.  TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells.

Authors:  Thanh Thao Vo Nguyen; Yukihide Watanabe; Aya Shiba; Masayuki Noguchi; Susumu Itoh; Mitsuyasu Kato
Journal:  Cancer Sci       Date:  2014-02-18       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.